412 related articles for article (PubMed ID: 37482684)
1. Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis.
Koh ES; Kim GH; Chung S
Endocrinol Metab (Seoul); 2023 Aug; 38(4):359-372. PubMed ID: 37482684
[TBL] [Abstract][Full Text] [Related]
2. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
Thomas MC; Cherney DZI
Diabetologia; 2018 Oct; 61(10):2098-2107. PubMed ID: 30132034
[TBL] [Abstract][Full Text] [Related]
3. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.
Bailey CJ; Day C; Bellary S
Curr Diab Rep; 2022 Jan; 22(1):39-52. PubMed ID: 35113333
[TBL] [Abstract][Full Text] [Related]
4. Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics.
Kim NH; Kim NH
Diabetes Metab J; 2022 Jul; 46(4):543-551. PubMed ID: 35929172
[TBL] [Abstract][Full Text] [Related]
5. Hemodynamic and renal implications of sodium-glucose cotransporter- 2 inhibitors in type 2 diabetes mellitus.
Tejedor Jorge A
Med Clin (Barc); 2016 Nov; 147 Suppl 1():35-43. PubMed ID: 28760224
[TBL] [Abstract][Full Text] [Related]
6. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
Silva Dos Santos D; Polidoro JZ; Borges-JĂșnior FA; Girardi ACC
Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
8. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
9. Renal Effects of Sodium-Glucose Co-Transporter Inhibitors.
Thomson SC; Vallon V
Am J Cardiol; 2019 Dec; 124 Suppl 1(Suppl 1):S28-S35. PubMed ID: 31741437
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
Liu B; Wang Y; Zhang Y; Yan B
Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
[TBL] [Abstract][Full Text] [Related]
11. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
Brady JA; Hallow KM
J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of sodium-glucose cotransporter 2 to slow the progression of chronic kidney disease.
Oguz F; Demoulin N; Thissen JP; Jadoul M; Morelle J
Acta Clin Belg; 2022 Aug; 77(4):805-814. PubMed ID: 34404335
[TBL] [Abstract][Full Text] [Related]
13. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
Vallon V; Thomson SC
Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
[TBL] [Abstract][Full Text] [Related]
14. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
[TBL] [Abstract][Full Text] [Related]
15. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus.
Kashiwagi A; Maegawa H
J Diabetes Investig; 2017 Jul; 8(4):416-427. PubMed ID: 28178390
[TBL] [Abstract][Full Text] [Related]
16. An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.
Salvatore T; Galiero R; Caturano A; Rinaldi L; Di Martino A; Albanese G; Di Salvo J; Epifani R; Marfella R; Docimo G; Lettieri M; Sardu C; Sasso FC
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409011
[TBL] [Abstract][Full Text] [Related]
17. SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.
van Bommel EJM; Muskiet MHA; Tonneijck L; Kramer MHH; Nieuwdorp M; van Raalte DH
Clin J Am Soc Nephrol; 2017 Apr; 12(4):700-710. PubMed ID: 28254770
[TBL] [Abstract][Full Text] [Related]
18. Renoprotective mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease.
Ravindran S; Munusamy S
J Cell Physiol; 2022 Feb; 237(2):1182-1205. PubMed ID: 34713897
[TBL] [Abstract][Full Text] [Related]
19. The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes.
Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Chattipakorn SC; Chattipakorn N; Lungkaphin A
Biomed Pharmacother; 2017 Oct; 94():176-187. PubMed ID: 28759755
[TBL] [Abstract][Full Text] [Related]
20. Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?
Rajasekeran H; Cherney DZ; Lovshin JA
Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):358-367. PubMed ID: 28582367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]